Abstracts tagged "COVID-19"

Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0753 • ACR Convergence 2022
Humoral Immune Response Against BNT162b2 mRNA COVID-19 Vaccine in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: A Japanese Monocentric Study
Koichi Sugihara¹, Risa Wakiya¹, Tomohiro Kameda¹, Hiromi Shimada¹, Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, mao mizusaki², Rina Mino¹ and Hiroaki Dobashi³, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: BNT162b2 is the most commonly used COVID-19 vaccine in Japan. The safety and efficacy of the vaccine was demonstrated in the general population, but…
Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Sara Tedeschi¹, Daniel Solomon¹, Yuezhou Chen², Jack Ellrodt¹, Mary Grace Whelan¹, Jacklyn Stratton¹, Keigo Hayashi³, Noah Whiteman², Lin Chen¹, Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Emma Gomez-Rivas¹, Deepak Rao¹, Anna Jonsson¹ and Duane Wesemann², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
Abstract Number: 0861 • ACR Convergence 2022
Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Amanda Neikirk², Yiling Yang², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on how rates of diagnosis of rheumatic diseases have changed during the COVID-19 pandemic. We compared rates of JIA diagnosis before…
Abstract Number: 1205 • ACR Convergence 2022
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases
Claire Cook¹, Naomi Patel², Xiaoqing Fu¹, Xiaosong Wang³, Yumeko Kawano³, Kathleen Vanni³, Grace Qian³, Emily Banasiak³, Emily Kowalski³, Hyon Choi⁴, yuqing zhang⁵, Jeffrey Sparks⁶ and Zachary Wallace¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Brigham and Women's Hospital, Boston, MA, ⁴MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁵Massachusetts General Hospital, Quincy, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) on immunomodulatory medications may be at particular risk for COVID-19 breakthrough infection given uncertain immune response to…
Abstract Number: 1706 • ACR Convergence 2022
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
Emmanuel Abimelec Camacho-Morán¹, jiram torres-Ruiz¹, Jaquelin Lira-Luna¹, Ana Sofía Vargas-Castro², Alfredo Pérez-Fragoso¹, Miroslava Nuñez-Aguirre², Beatriz Alcalá-Carmona³, Abdiel Absalón-Aguilar³ and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Post-COVID19 syndrome has been defined as the persistence of symptoms and/or organic damage for more than three weeks after the presence of clinical infection…
Abstract Number: 1924 • ACR Convergence 2022
Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
Thomas Renson¹, Nils Forkert¹, Kimberly Amador¹, Paivi Miettunen¹, Simon Parsons¹, Muhammed Dhalla¹, Nicole Johnson², Nadia Luca², Heinrike Schmeling¹, Rebeka Stevenson¹, Marinka Twilt¹, Lorraine Hamiwka¹ and Susanne Benseler¹, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: The COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) is characterized by Kawasaki disease (KD)-like mucocutaneous features. The clinical course is often unpredictable. The goals…
Abstract Number: 2187 • ACR Convergence 2022
Decision-Making Around Vaccination and Other Public Health Measures During the COVID-19 Pandemic: Experiences of Individuals with Rheumatoid Arthritis
Jenny leese¹, Stephanie Therrien², Smruthi Ramachandran³, Catherine L. Backman³, Jasmin Ma⁴, Kelly English⁵, Eileen Davidson⁶, Shanon McQuitty⁷, Alison Hoens⁵, Cheryl Koehn⁸, James Gavin⁹, jo Adams⁹ and Linda Li³, ¹University of Ottawa, Ottawa, ON, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada/University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Patient Advisory Board of Arthritis Research Canada, Burnaby, BC, Canada, ⁷Arthritis Patient Advisory Board of Arthritis Research Canada, Richmond, BC, Canada, ⁸Arthritis Consumer Experts, Vancouver, BC, Canada, ⁹University of Southampton, Southampton, United Kingdom
Background/Purpose: The spectrum of individual decisions about adopting public health measures (e.g., vaccination programs, physical distancing, mask wearing) to reduce COVID-19 transmission has important implications…
Abstract Number: 0163 • ACR Convergence 2022
Changes in Juvenile Dermatomyositis After the COVID-19 Pandemic
Christopher Costin¹, Gabrielle Morgan², Amer Khojah³ and Lauren Pachman⁴, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Prior research has shown that viruses may trigger JDM, although the degree to which COVID-19 may serve as a trigger for JDM remains unknown.…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 0755 • ACR Convergence 2022
Immune Responses and Disease Marker Changes Following SARS-CoV-2 mRNA Vaccination in a Cohort of Rheumatic Disease Patients
Zesheng An¹, Xian Zhou¹, Yanfeng Li¹, Jane Jaquith¹, Kathleen McCarthy-Fruin¹, Kenneth J. Warrington¹, Ali Duarte-Garcia¹, Uma Thanarajasingam¹, Cornelia M. Weyand² and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic School of Medicine, Rochester, MN, and Stanford University, Stanford, CA
Background/Purpose: The immunological responses following 3 doses of SARS-CoV2 mRNA vaccination in rheumatic disease patients are unclear. Furthermore, the impact of SARS-CoV2 mRNA vaccination on…
Abstract Number: 0788 • ACR Convergence 2022
Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study
Tal Gazitt¹, Jacqueline Shear², Joy Feld³, Amir Haddad⁴, Muna Elias⁵, Nizar Hijazi⁶, Idit Lavi¹, Tali Eviatar⁷, Victoria Furer⁸, Hagit Peleg⁹, Ori Elkayam¹⁰ and Devy Zisman¹, ¹Carmel Medical Center, Haifa, Israel, ²The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Carmel Medical Centre, Haifa, Israel, ⁵Carmel Medical Center, Rheumatology Unit, Haifa, Israel, ⁶Carmel medical centre1Carmel Medical Center, Rheumatology Unit, Haifa, Israel, ⁷Tel Aviv Sourasky medical center, Tel Aviv, Israel, ⁸Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, ⁹Hadassah Medical Center, Jerusalem, Israel, ¹⁰Tel Aviv Medical Center, Rheumatology, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: Little is known regarding autoantibody generation and clinically manifest autoimmunity following BNT162b2 mRNA vaccination. Our objective was to investigate the development of autoantibodies following…
Abstract Number: 0862 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data
Daniel Horton¹, Yiling Yang², Amanda Neikirk², Cecilia Huang³, Stephen Crystal⁴, amy davidow⁵, Kevin Haynes⁶, Tobias Gerhard⁷, Carlos Rose⁸, Brian Strom⁹ and Lauren Parlett², ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁴Rutgers Center for Health Services Research, New Brunswick, NJ, ⁵New York University, New York, NY, ⁶Johnson & Johnson, Titusville, NJ, ⁷Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, ⁸Nemours, Chadds Ford, PA, ⁹Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…
Abstract Number: 1212 • ACR Convergence 2022
Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
Kastriot Kastrati¹, Daniel Mrak², Peter Weber³, Lena Goethans³, Claudia Hana³, Elisabeth Simader², Thomas Hummel³, Eleonora Friedberg³, Daniel Aletaha⁴, Michael Bonelli² and Helga Radner², ¹Division of Rheumatology, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of severe COVID-19 disease courses. Real-world data on immunogenicity are scarce but crucial to…
Abstract Number: 1744 • ACR Convergence 2022
Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases
Cristiana Sieiro Santos¹, Sara Calleja Antolín¹, Clara Moriano Morales², Carolina Álvarez Castro¹, Elvira Díez Álvarez¹ and Jose Maria Ruiz de Morales¹, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital León, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].